Topic outline
- General
- Background
Background
Overview: This training toolkit by the European Laboratory Initiative for TB, HIV and Viral Hepatitis provides a unique combination of practical guidance and expert advice on the interpretation of selected WHO-endorsed tests for drug-resistant tuberculosis (DR-TB). More specifically, it covers the latest guidance for the interpretation of rapid molecular assays for DR-TB by Cepheid (GeneXpert MTB/RIF and GeneXpert MTB/RIF Ultra) and Hain Lifescience (GenoTypeMTBDRplus VER 2.0 and GenoTypeMTBDRsl VER 2.0). Participants can exchange experiences through a course forum. Laboratory experts are available to address key questions via the forum and a dedicated pilot email service
Course duration: Approximately 5 hours (2 for the online modules and 3 for the practical examples)
Certificates: A Record of Achievement is offered at the end of the course upon passing 80% of test questions. Participants who receive a Record of Achievement can also download an Open Badge for this course. Click here to learn how.
- Learning Objective
Learning Objective
Learning objective: By the end of this course, you should be able to implement the latest WHO guidelines for the interpretation of Xpert, Ultra, FL-LPA and SL-LPA for gDST.
- Course contents
Course contents
Introduction:
Welcome message by Dr Masoud Dara, Coordinator, Communicable Diseases, WHO Regional Office for Europe.Module A. Principles of genotypic drug-susceptibility testing:
By the end of this module, participants should understand how mutations cause drug-resistance, the strength and limitations of gDST testing, and the reasons for the changes to the interpretation of WHO-endorsed gDST assays.Module B. Changes to the interpretation of genotypic drug-susceptibility testing assays:
By the end of this module, participants should understand the minor changes to the interpretation of Xpert and Ultra and how to use the ELI interpretation guide and ELI interpretation templates to implement the major changes to the interpretation of the FL-LPA and SL-LPA.Module C. Hain line-probe assays: ramp rate and troubleshooting:
By the end of this module, participants should understand the importance of using the correct ramp rate for the LPAs and how to resolve other problems with these assays.Module D. How to minimize contamination:
By the end of this module, participants should understand the different approaches to minimize contamination in laboratories.Important updates and frequently asked questions:
Notable findings from the scientific literature and frequent questions from participants will be shared in this section.
- Where to find these materials?
Where to find these materials?
You can take this e-learning on the WHO platform, OpenWHO, following this link
Note, if you don't have a WHO account you may need to create a new one. Alternatively you may take the course as guest without getting a certificate.